US 11,787,871 B2
Methods for the treatment of disease using immunoglobulins having fc regions with altered affinities for FcgammaRactivating and FegammaRinhibiting
Jeffrey B. Stavenhagen, Rockville, MD (US); and Scott Koenig, Rockville, MD (US)
Assigned to MacroGenics, Inc., Rockville, MD (US)
Filed by MacroGenics, Inc., Rockville, MD (US)
Filed on May 29, 2020, as Appl. No. 16/886,964.
Application 16/886,964 is a continuation of application No. 15/621,710, filed on Jun. 13, 2017, granted, now 10,711,069.
Application 15/621,710 is a continuation of application No. 14/156,747, filed on Jan. 16, 2014, granted, now 9,708,408, issued on Jul. 18, 2017.
Application 14/156,747 is a continuation of application No. 11/952,568, filed on Dec. 7, 2007, granted, now 8,652,466, issued on Feb. 18, 2014.
Claims priority of provisional application 60/869,254, filed on Dec. 8, 2006.
Prior Publication US 2020/0392245 A1, Dec. 17, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. C07H 21/02 (2006.01); C07H 21/04 (2006.01); C12P 21/06 (2006.01); C12P 21/04 (2006.01); C12N 5/02 (2006.01); C12N 1/20 (2006.01); C12N 15/00 (2006.01); C07K 16/30 (2006.01); C07K 16/28 (2006.01); C07K 16/00 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/30 (2013.01) [C07K 16/2887 (2013.01); A61K 2039/505 (2013.01); C07K 2317/71 (2013.01); C07K 2317/72 (2013.01); C07K 2317/732 (2013.01); C07K 2317/734 (2013.01)] 20 Claims
 
1. An isolated nucleic acid molecule comprising a nucleotide sequence encoding an antibody which comprises an antigen binding region and a variant Fc region, wherein said variant Fc region is a variant of a human IgG Fc region, and said variant Fc region comprises the following amino acid modifications relative to a wild-type Fc region: F243L, R292P and Y300L, wherein the positions are numbered according to the EU index as in Kabat.